These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 8357473

  • 1. [Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
    Sabbah A, Lesellin J, Hassoun S, Sicard H, André C.
    Allerg Immunol (Paris); 1993 Jun; 25(6):241-7. PubMed ID: 8357473
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.
    Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H.
    Allergy; 1994 May; 49(5):309-13. PubMed ID: 8092425
    [Abstract] [Full Text] [Related]

  • 3. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ, Antvelink JB, Luwema RA.
    Allergol Immunopathol (Madr); 1998 May; 26(5):234-40. PubMed ID: 9885731
    [Abstract] [Full Text] [Related]

  • 4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [Abstract] [Full Text] [Related]

  • 5. Rush immunotherapy with sublingual administration of grass allergen extract.
    Feliziani V, Marfisi RM, Parmiani S.
    Allergol Immunopathol (Madr); 1993 Apr; 21(5):173-8. PubMed ID: 8160561
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR, UK Immunotherapy Study Group.
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [Abstract] [Full Text] [Related]

  • 7. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR, Riis B.
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P, Petrás M, Sýkora T, Lesná I.
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
    Worm M.
    Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
    [Abstract] [Full Text] [Related]

  • 10. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ.
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W.
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [Abstract] [Full Text] [Related]

  • 12. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B.
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [Abstract] [Full Text] [Related]

  • 13. Monoid sublingual immunotherapy.
    Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML.
    Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
    [Abstract] [Full Text] [Related]

  • 14. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A, Melac M, Montagut A, Lhéritier-Barrand M, Tabar A, Worm M.
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [Abstract] [Full Text] [Related]

  • 15. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.
    Giovannini M, Braccioni F, Sella G, Contoli M, Perri G, Frati F, Incorvaia C.
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):69-71. PubMed ID: 15859367
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.
    Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP.
    Allergol Immunopathol (Madr); 1995 Feb; 23(5):224-30. PubMed ID: 8526180
    [Abstract] [Full Text] [Related]

  • 17. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R, Stender A, Rak S.
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [Abstract] [Full Text] [Related]

  • 18. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G, Hurley C, Turcanu V, Lack G.
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.